RxDoctor Payments Data

Brian Ferris

Vascular Surgery · Bellevue, WANPI 1104859081

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $118,323 of the $169,710 with a category attached, or 69.7%. Johnson & Johnson accounts for 65.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $90,033 and has fallen 99.9% since, to $109 in 2025. Among vascular surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$169,710in general payments, 2019–2025

Across 254 payments — averaging $668.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$111K
  • Boston Scientific$24K
  • Biocompatibles, Inc.$23K
  • Medtronic$10K
  • Philips North America LLC$538
  • Cook Medical LLC$296
  • plus $858 from 14 others
$43,811in research payments, 2019–2025

Across 18 payments — averaging $2433.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$31K
  • Abbott$12K

What the payments were for

  • Consulting fees$19,87012%
  • Speaking & faculty fees$118,32370%
  • Travel & lodging$24,03214%
  • Food & beverage$7,3774%
  • Education$1080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$169,710 in reported general payments places this provider in the 95th percentile of 111 vascular surgery providers in Washington.

See all vascular surgery providers in Washington

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban212$224,129
EliquisApixaban45$52,817
Atorvastatin Calcium40$551
Rosuvastatin Calcium29$472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$111,364$224,129212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 vascular surgery providers in Washington.

Other vascular surgery in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →